China Proposes 12 Months Exclusivity For First Generics
NMPA Issues Draft Guideline Rewarding Patent Challengers
China’s National Medical Products Administration has released key regulations and proposals designed to encourage first generics through a 12-month market exclusivity proposal.
You may also be interested in...
In the latest sign that some multinationals are scaling down operations in the world's second-largest pharma market, Mundipharma is reported to be exploring the sale of its business in China, with a large group of bidders including state-owned Sinopharm and local private equity firm Boyu Capital in the running.
Facing a increasingly competitive environment and tense bilateral relationship, US biotechs must innovate and differentiate while protecting their innovations in China, say panelists at the BIO annual conference.
The Biden Administration’s pledge to provide 500 million doses of Pfizer/BioNTech's COVID-19 vaccines is a direct blow to China’s global vaccine diplomacy push.